Travere Therapeutics, Inc. TVTX EBITDA margin
EBITDA margin at other companies
Other financials
Where this comes from
Calculated from Travere Therapeutics, Inc.’s reported figures.
Based on trailing twelve months.
The official record: Travere Therapeutics, Inc.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Travere Therapeutics, Inc.'s ebitda margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Travere Therapeutics, Inc.'s EBITDA margin?
- Travere Therapeutics, Inc. (TVTX) reported EBITDA margin of 3% in Q1 2026.
- How has Travere Therapeutics, Inc.'s EBITDA margin changed year-over-year?
- Travere Therapeutics, Inc.'s EBITDA margin increased by 104.5% year-over-year, from -66.1% to 3%.
- What is the long-term trend for Travere Therapeutics, Inc.'s EBITDA margin?
- Over 4 years (2020 to 2025), Travere Therapeutics, Inc.'s EBITDA margin has grown at a -72.7% compound annual growth rate (CAGR), from -76.4% to -0.4%.
- What does EBITDA margin mean?
- EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.